Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...

74 year-old male with history of multiple PCI, PAD, Type 2 DM, presented a symptomatic bicuspid aortic stenosis with a preserved LV function.

They implant a myval 26 mm by right femoral artery access with a right radial secondary access, after a predilation (Balloon 20mm). They prepare...

A 65-year-old female with a history of diabetes and moderate left ventricular dysfunction (LVEF 50%) presented with symptomatic severe bicuspid aortic stenosis associated with moderate-to-severe aortic regurgitation. A 26 mm Sapien Resilia valve was implanted under local anesthesia via femoral artery access, with right radial secondary...

A study to determine the long-term outcomes of high-risk patients who underwent transcatheter aortic valve implantation with the third-generation CoreValve device, according to the 2017 EAPCI/ESC/EACTS definition of valve durability.

Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.

The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications. 

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)